2020-10-25
The Ministry of Regional Development just released results of the competition 2.1 PO IR (Support for R@D center). Poltreg S.A. has been scored the highest 28 points and received grant = 10 597 978,30 PLN (≈2.4mln Euro) for the infrastructure.
More:
https://www.poir.gov.pl/media/94731/Projekty_rekomendowane_do_wsparcia.pdf
2026-01-21
Immuthera appoints Dr. Antionette Moran, Dr. Jason Gaglia, and Dr. Jeffrey Cohen, Renowned Endocrinologists, Diabetologists and Neuroscientist to the Scientific Advisory Board (SAB)
2026-01-12
Immuthera announces global exclusive license from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg platform for autoimmune and inflammatory diseases
2025-11-27
PolTREG published data in a prestigious scientific journal demonstrating the long-term effectiveness of TREG cell therapy, which can halt the development of type 1 diabetes in children
2025-11-14
World Diabetes Day. PolTREG is developing a therapy that can stop the development of type 1 diabetes in children.
2025-11-07
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
